Publications by authors named "S Jhee"
Article Synopsis
- - Rapid advancements in the internet of things (IoT) have led to the development of various health monitoring technologies, requiring an efficient power supply for operation.
- - The paper discusses self-powered triboelectric sensors (TESs) made from GaN nanowires and polydimethylsiloxane (PDMS), designed to imitate human skin layers to enhance performance.
- - The TESs demonstrated a significant output with a maximum voltage of 14.7 V and a power density of 63.7 mW when touched, exceeding previous performance benchmarks.
Stretchable photosensors, which operate in the wavelength window of 1.3 μm, were fabricated with InN nanowires (NWs) and graphene to serve as a light-absorbing medium and carrier channel, respectively. Specifically, the stretchable photosensors were fabricated by transferring InN NWs embedded in graphene layers onto polyurethane substrates pre-stretched at the strain levels of 10, 20, 30, 40, 50, and 60%.
View Article and Find Full Text PDFBackground: The development of beta-site amyloid-beta precursor protein cleaving enzyme (BACE) 1 inhibitors for the treatment of Alzheimer's disease requires optimization of inhibitor potency, selectivity, and brain penetration. Moreover, there is a need for low-dose compounds since liver toxicity was found with some BACE inhibitors.
Objective: To determine whether the high potency and robust pharmacodynamic effect of the BACE inhibitor LY3202626 observed in nonclinical species translated to humans.
Background: Eflapegrastim (Rolontis) is a novel long-acting pegylated recombinant human granulocyte colony-stimulating factor (G-CSF). Eflapegrastim has been developed to reduce the duration and incidence of chemotherapy-induced neutropenia in cancer patients using patient-friendly, less-frequent administration.
Objective: This phase I study aimed to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and immunogenicity of eflapegrastim following a single subcutaneous administration to healthy Japanese and Caucasian subjects.
Background: KM-819 is a novel FAS-associated factor 1 (FAF1) inhibitor, and a neuroprotective agent, under clinical development for the treatment of Parkinson's disease as a disease-modifying drug.
Methods: This first-in-human, single and multiple ascending dose study investigated the safety, tolerability, pharmacokinetics, and pharmacodynamics of KM-819 in healthy volunteers. Additionally, the effect of age on safety and pharmacokinetics were assessed.